As such, it is possible that our results may have been different if samples were in storage for a greater duration of time
The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development. (8) Ipamorelin may have exhibited a propensity to elevate growth hormone levels, potentially reaching heights of up to 80mIU/l (equivalent to an approximate concentration of 26.6ng/ml)
Your doctor can do a blood test if youre concerned
It transforms the conversation from "I feel tired and bloated" to "I have noticed my B12 and Ferritin are at the lower end of the range
Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
Research overview Related protocols and comparisons GHK-Cu (50 mg Vial) Dosage Protocol GHK-Cu (100 mg Vial) Dosage Protocol BPC-157 (5 mg Vial) Dosage Protocol BPC-157 (10 mg Vial) Dosage Protocol TB-500 (5 mg Vial) Dosage Protocol TB-500 (10 mg Vial) Dosage Protocol BPC-157 + TB-500 (10 mg Blend) Dosage Protocol BPC-157 + TB-500 (20 mg Blend) Dosage Protocol